ALK and non-small cell lung carcinoma: PROFILE 1001 was a multicenter phase II study whose first results were published in 2010, which investigated both the safety and efficacy of crizotinib administered orally and daily in 28-day cycles to patients affected by NSCLC with occurring ALK rearrangements.